Post progression survival in glioblastoma: where are we?

被引：11

作者：

Franceschi, Enrico ^{[1
]}

Ermani, Mario ^{[2
]}

Bartolini, Stefania ^{[1
]}

Bartolotti, Marco ^{[1
]}

Poggi, Rosalba ^{[1
]}

Tallini, Giovanni ^{[3
]}

Marucci, Gianluca ^{[3
]}

Fioravanti, Antonio ^{[4
]}

Tosoni, Alicia ^{[1
]}

Agati, Raffaele ^{[5
]}

Bacci, Antonella ^{[5
]}

Pozzati, Eugenio ^{[4
]}

Morandi, Luca ^{[3
]}

Balestrini, Damiano ^{[6
]}

Ghimenton, Claudio ^{[7
]}

Crisi, Girolamo ^{[8
]}

Brandes, Alba A. ^{[1
]}

机构：

[1] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Med Oncol, I-40139 Bologna, Italy

[2] Azienda Osped Univ, Neurosci Dept, Statist & Informat Unit, Padua, Italy

[3] Univ Bologna, Bellaria Hosp, Sect Pathol, Dept Biomed & NeuroMotor Sci DiBiNeM, Bologna, Italy

[4] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Neurosurg, Bologna, Italy

[5] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Neuroradiol, Bologna, Italy

[6] Azienda USL IRCCS Inst Neurol Sci, Bellaria Maggiore Hosp, Dept Radiotherapy, Bologna, Italy

[7] Verona Hosp, Dept Pathol, Verona, Italy

[8] Univ Hosp Parma, Dept Neuroradiol, I-43100 Parma, Italy

来源：

JOURNAL OF NEURO-ONCOLOGY | 2015年 / 121卷 / 02期

关键词：

Glioblastoma; Recurrence; End points; Progression-free survival; Post-progression survival; BEVACIZUMAB PLUS IRINOTECAN; HIGH-GRADE GLIOMAS; PHASE-II TRIAL; RECURRENT GLIOBLASTOMA; PROMOTER METHYLATION; MALIGNANT GLIOMA; END-POINT; TEMOZOLOMIDE; MULTIFORME; LOMUSTINE;

D O I：

10.1007/s11060-014-1651-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The optimal end point for phase II studies for recurrent glioblastoma (GBM) is unclear and a matter of debate. Moreover, data about post-progression survival (PPS) after the first disease progression in GBM patients treated according to EORTC 26981/22981/NCIC CE. 3 trial are limited. The aim of this study was to evaluate the PPS in GBM patients. The analysis was made with a database on 1,006 GBM patients followed prospectively between 06/2005 and 06/2010. Eligibility criteria for the study were: age >= 18 years; PS: 0-2; chemotherapy given at disease progression after RT/TMZ. 232 patients (mean age 52 years, range 18-77 years) were enrolled. The median PFS following second line chemotherapy (PFS2) was 2.5 months (95% CI 2.1-2.9) and the rate of patients free of progression at 6 months (PFS2-6 mo), was 21.6% (95% CI 16.3-26.9%). The median PPS was 8.6 months (95% CI 7.4-9.8), PPS rates were: PPS-6: 66% (95% CI 60.3-72.9%), PPS-9: 48.2% (95% CI 41.5-54.9%) and PPS-12: 31.7% (95% CI 25.2-38.2%). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM.

引用

页码：399 / 404

页数：6

共 16 条

[1] The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme [J].

Ballman, Karla V. ;

Buckner, Jan C. ;

Brown, Paul D. ;

Giannini, Caterina ;

Flynn, Patrick J. ;

LaPlant, Betsy R. ;

Jaeckle, Kurt A. .

NEURO-ONCOLOGY, 2007, 9 (01) :29-38

[2] Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma [J].

Batchelor, Tracy T. ;

Mulholland, Paul ;

Neyns, Bart ;

Nabors, L. Burt ;

Campone, Mario ;

Wick, Antje ;

Mason, Warren ;

Mikkelsen, Tom ;

Phuphanich, Surasak ;

Ashby, Lynn S. ;

DeGroot, John ;

Gattamaneni, Rao ;

Cher, Lawrence ;

Rosenthal, Mark ;

Payer, Franz ;

Juergensmeier, Juliane M. ;

Jain, Rakesh K. ;

Sorensen, A. Gregory ;

Xu, John ;

Liu, Qi ;

van den Bent, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3212-3218

[3] Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study [J].

Brandes, Alba A. ;

Tosoni, Alicia ;

Cavallo, Giovanna ;

Reni, Michele ;

Franceschi, Enrico ;

Bonaldi, Laura ;

Bertorelle, Roberta ;

Gardiman, Marina ;

Ghimenton, Claudio ;

Iuzzolino, Paolo ;

Pession, Annalisa ;

Blatt, Valeria ;

Ermani, Mario .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4746-4753

[4] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].

Friedman, Henry S. ;

Prados, Michael D. ;

Wen, Patrick Y. ;

Mikkelsen, Tom ;

Schiff, David ;

Abrey, Lauren E. ;

Yung, W. K. Alfred ;

Paleologos, Nina ;

Nicholas, Martin K. ;

Jensen, Randy ;

Vredenburgh, James ;

Huang, Jane ;

Zheng, Maoxia ;

Cloughesy, Timothy .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740

[5] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma [J].

Kreisl, Teri N. ;

Kim, Lyndon ;

Moore, Kraig ;

Duic, Paul ;

Royce, Cheryl ;

Stroud, Irene ;

Garren, Nancy ;

Mackey, Megan ;

Butman, John A. ;

Camphausen, Kevin ;

Park, John ;

Albert, Paul S. ;

Fine, Howard A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :740-745

[6] Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas [J].

Lamborn, Kathleen R. ;

Yung, W. K. Alfred ;

Chang, Susan M. ;

Wen, Patrick Y. ;

Cloughesy, Timothy F. ;

DeAngelis, Lisa M. ;

Robins, H. Ian ;

Lieberman, Frank S. ;

Fine, Howard A. ;

Fink, Karen L. ;

Junck, Larry ;

Abrey, Lauren ;

Gilbert, Mark R. ;

Mehta, Minesh ;

Kuhn, John G. ;

Aldape, Kenneth D. ;

Hibberts, Janelle ;

Peterson, Pamela M. ;

Prados, Michael D. .

NEURO-ONCOLOGY, 2008, 10 (02) :162-170

[7] RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA [J].

MACDONALD, DR ;

CASCINO, TL ;

SCHOLD, SC ;

CAIRNCROSS, JG .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1277-1280

[8]

Palmisano WA, 2000, CANCER RES, V60, P5954

[9] Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide [J].

Polley, Mei-Yin C. ;

Lamborn, Kathleen R. ;

Chang, Susan M. ;

Butowski, Nicholas ;

Clarke, Jennifer L. ;

Prados, Michael .

NEURO-ONCOLOGY, 2010, 12 (03) :274-282

[10] Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].

Stupp, R ;

Mason, WP ;

van den Bent, MJ ;

Weller, M ;

Fisher, B ;

Taphoorn, MJB ;

Belanger, K ;

Brandes, AA ;

Marosi, C ;

Bogdahn, U ;

Curschmann, J ;

Janzer, RC ;

Ludwin, SK ;

Gorlia, T ;

Allgeier, A ;

Lacombe, D ;

Cairncross, JG ;

Eisenhauer, E ;

Mirimanoff, RO ;

Van Den Weyngaert, D ;

Kaendler, S ;

Krauseneck, P ;

Vinolas, N ;

Villa, S ;

Wurm, RE ;

Maillot, MHB ;

Spagnolli, F ;

Kantor, G ;

Malhaire, JP ;

Renard, L ;

De Witte, O ;

Scandolaro, L ;

Vecht, CJ ;

Maingon, P ;

Lutterbach, J ;

Kobierska, A ;

Bolla, M ;

Souchon, R ;

Mitine, C ;

Tzuk-Shina, T ;

Kuten, A ;

Haferkamp, G ;

de Greve, J ;

Priou, F ;

Menten, J ;

Rutten, I ;

Clavere, P ;

Malmstrom, A ;

Jancar, B ;

Newlands, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :987-996

← 1 2 →